Claims for Patent: 11,419,842

Summary for Patent: 11,419,842

Title:	Neutral pH compositions of Docetaxel and human serum albumin
Abstract:	This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.
Inventor(s):	Qun Sun
Assignee:	Zhuhai Beihai Biotech Co Ltd
Application Number:	US16/345,615
Patent Claims:	1. A pharmaceutical composition comprising a non-covalently bound complex comprising Docetaxel and human serum albumin, wherein the molar ratio of Docetaxel and the human serum albumin in the composition is from about 0.1:1 to about 5:1, wherein the composition is a clear aqueous solution, wherein the human serum albumin in the composition is from commercial pharmaceutical human serum albumin solution for infusion, wherein the docetaxel concentration in the solution is higher than aqueous solubility of docetaxel, and wherein pH of the composition is from about 5 to about 8. 2. The composition of claim 1, wherein the molar ratio of Docetaxel and the human serum albumin is from about 0.5:1 to about 2:1. 3. The composition of claim 1, wherein the molar ratio of Docetaxel and the human serum albumin is about 1:1. 4. The composition of claim 1, wherein pH of the composition is from about 5.5 to about 7.5. 5. A method for the preparation of the composition of claim 1, said method comprising: mixing an organic solution of Docetaxel in a polar water-miscible organic solvent and a first aqueous solution containing human serum albumin to form a second aqueous solution, wherein the second aqueous solution is a clear aqueous solution. 6. The method of claim 5, further comprising removing said polar water miscible organic solvent and water from the second aqueous solution. 7. A pharmaceutical composition comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:50 to about 1:1000, wherein the composition is a clear aqueous solution, wherein the human serum albumin in the composition is from commercial pharmaceutical human serum albumin solution for infusion, wherein the docetaxel concentration in the solution is higher than aqueous solubility of docetaxel, and wherein pH of the composition is from about 5 to about 8. 8. The composition of claim 7, wherein the Docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:60 to about 1:300. 9. The composition of claim 7, wherein the Docetaxel and the human serum albumin in the composition have a ratio by weight from about 1:80 to about 1:200. 10. The composition of claim 7, wherein the composition is substantially free of solvent other than water. 11. The composition of claim 7, wherein the composition is a clear aqueous solution for at least 3 hours. 12. A method of treating a cancer, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 1. 13. The method of claim 12, wherein the cancer is selected from the group consisting of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, head and neck cancer, ovarian cancer, pancreatic cancer, and Kaposi's sarcoma.